PDGFRB and neoplasm: Similarly, anlotinib is a new type of anti-angiogenic small-molecule TKI whose major targets are VEGFR1-3, FGFR1-4, PDGFR-α, PDGFR-β, and stem cell factor receptors, which inhibit tumor angiogenesis and growth19–21.